A 45-year-old male smoker (40 pack-year history) presents with a 6-month history of insidious dyspnea and dry cough. Examination reveals bibasilar inspiratory crackles without clubbing. HRCT chest shows centrilobular ground-glass nodules with upper-lobe predominant emphysema. BAL demonstrates >95% pigmented macrophages with golden-brown granules. Surgical lung biopsy confirms respiratory bronchioles filled with pigmented macrophages, consistent with RB-ILD. Which of the following management approaches best reflects the approach marked **A** in the diagram?
A. Empirical anti-tuberculosis therapy for 6 months pending sputum AFB culture results
B. Urgent referral for lung transplantation evaluation given the progressive nature of RB-ILD
C. Immediate high-dose intravenous cyclophosphamide and azathioprine to arrest macrophage infiltration
D. Smoking cessation counseling with close follow-up; oral prednisolone 0.5–1 mg/kg/day initiated only if symptoms persist or progress despite quitting
Explanation
Why option 1 is correct
Smoking cessation is the cornerstone of management for smoking-related interstitial lung diseases (RB-ILD, DIP, and the RB-ILD/DIP spectrum). The ATS/ERS IIP Classification 2013 and Harrison's 21st edition emphasize that most patients with RB-ILD stabilize or improve over months after smoking cessation alone. Oral corticosteroids (prednisolone 0.5–1 mg/kg/day tapered over 3–6 months) are reserved exclusively for patients with persistent or progressive symptoms despite smoking cessation. This stepwise approach—cessation first, corticosteroids only if needed—is the evidence-based standard and reflects the excellent prognosis of RB-ILD (>75% 5-year survival) when managed appropriately.
Why each distractor is wrong
Option 2 (High-dose cyclophosphamide and azathioprine): These aggressive immunosuppressive agents are not indicated in RB-ILD. They are reserved for rapidly progressive or life-threatening interstitial pneumonias (e.g., acute exacerbations of IPF or connective-tissue-disease-associated ILD), not for smoking-related disease where cessation is curative.
Option 3 (Urgent lung transplantation): RB-ILD has a favorable prognosis (>75% 5-year survival) and is not a progressive disease requiring early transplant evaluation. Transplantation is considered only in advanced, refractory cases—not as initial management.
Option 4 (Empirical anti-tuberculosis therapy): The clinical and histopathologic picture is diagnostic of RB-ILD (pigmented macrophages, centrilobular nodules, absence of acid-fast bacilli on BAL). TB is not in the differential and empirical anti-TB therapy would delay appropriate management and expose the patient to unnecessary toxicity.
High-YieldNEET PG
Smoking cessation alone is sufficient for most RB-ILD patients; corticosteroids are second-line only for persistent/progressive symptoms—this distinguishes RB-ILD from IPF and other progressive ILDs.
ATS/ERS IIP Classification 2013; Harrison's Principles of Internal Medicine, 21st ed
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
